Telmisartan in high-risk patients intolerant of ACE inhibitors

The Lancet

Volumn 373, Issue 9662, 2009, Pages 457-458

  Thompson, Matthew ^a   Heneghan, Carl ^b   Perera, Rafael ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; TELMISARTAN;

ANALYTICAL ERROR; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CLINICAL TRIAL; COMPARATIVE STUDY; DATA ANALYSIS; DRUG EFFECT; DRUG HYPERSENSITIVITY; DRUG RESEARCH; DRUG SAFETY; DRUG TOLERANCE; HEART FAILURE; HIGH RISK PATIENT; HUMAN; HYPERTENSION; LETTER; PRIORITY JOURNAL; RISK REDUCTION; TREATMENT OUTCOME;

EID: 59249086066     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(09)60161-6     Document Type: Letter

References (4)

1. The Telmisartan Randomised AssesssmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 372 (2008) 1174-1183
2. Montori V.M., Busse J.W., Permanyer-Miralda G., Ferreira I., and Guyatt G.H. How should clinicians interpret results reflecting the effect of an intervention on composite endpoints: should I dump this lump?. ACP J Club 143 (2005) A8
3. Dickersin K., and Min Y.I. Publication bias: the problem that won't go away. Ann N Y Acad Sci 703 (1993) 135-146
4. McCormack J., and Greenhalgh T. Seeing what you want to see in randomised controlled trials: versions and perversions of UKPDS data. BMJ 320 (2000) 1720-1723